drospirenone

Details

Files
Generic Name:
drospirenone
Project Status:
Active
Therapeutic Area:
Contraceptive, oral
Manufacturer:
Duchesnay Inc.
Call for patient/clinician input open:
Brand Name:
Slynd
Project Line:
Reimbursement Review
Project Number:
SR0806-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Slynd (drospirenone) is indicated for conception control in adolescent and adult women.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
​Slynd (drospirenone) is indicated for conception control in adolescent and adult women.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input openJune 30, 2023
Call for patient/clinician input closedAugust 25, 2023
Clarification:

- No patient input submission received

Submission receivedAugust 14, 2023
Submission acceptedAugust 30, 2023
Review initiatedAugust 31, 2023
Clarification:

- Submission was not accepted for review on 28 Aug 2023

Draft CADTH review report(s) provided to sponsor for commentNovember 24, 2023
Deadline for sponsors commentsDecember 05, 2023
CADTH review report(s) and responses to comments provided to sponsorJanuary 12, 2024
Expert committee meeting (initial)January 24, 2024
Draft recommendation issued to sponsorFebruary 06, 2024
Draft recommendation posted for stakeholder feedbackFebruary 15, 2024
End of feedback periodMarch 01, 2024
Final recommendation issued to sponsor and drug plansMarch 18, 2024
Final recommendation postedApril 04, 2024
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)April 02, 2024
CADTH review report(s) posted-